BR112016002001A2 - Medicamento compreendendo anticorpo antifosfolipase d4 - Google Patents
Medicamento compreendendo anticorpo antifosfolipase d4Info
- Publication number
- BR112016002001A2 BR112016002001A2 BR112016002001A BR112016002001A BR112016002001A2 BR 112016002001 A2 BR112016002001 A2 BR 112016002001A2 BR 112016002001 A BR112016002001 A BR 112016002001A BR 112016002001 A BR112016002001 A BR 112016002001A BR 112016002001 A2 BR112016002001 A2 BR 112016002001A2
- Authority
- BR
- Brazil
- Prior art keywords
- phospholipase
- present application
- antibody
- drug
- pld4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
MEDICAMENTO COMPREENDENDO ANTICORPO ANTIFOSFOLIPASE D4. O presente pedido fornece os medicamentos compreendendo os anticorpos que se ligam à fosfolipase D4(PLD4) assim como um método usando os ditos medicamentos para detectar e suprimir células B ativadas. O presente pedido é direcionado ainda à terapia de doenças autoimunes e alérgicas, resultando da função ativo-repressora. De modo a resolver estes problemas, o presente pedido fornece um anticorpo monoclonal que se liga ao domínio extracelular da proteína da fosfolipase D4 (PLD4), ou um fragmento contendo uma região de ligação de antígeno do mesmo como um ingrediente ativo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013158258 | 2013-07-30 | ||
| JP2013-158258 | 2013-07-30 | ||
| PCT/JP2014/070661 WO2015016386A1 (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016002001A2 true BR112016002001A2 (pt) | 2017-08-29 |
| BR112016002001B1 BR112016002001B1 (pt) | 2023-04-25 |
Family
ID=51493000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016002001-4A BR112016002001B1 (pt) | 2013-07-30 | 2014-07-30 | Uso de anticorpo monoclonal, método in vitro para detectar células b ativadas, reagente para detectar células b ativadas, método in vitro para suprimir a atividade b das células ativadas, e anticorpo monoclonal |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20160168266A1 (pt) |
| EP (1) | EP3027656B1 (pt) |
| JP (3) | JP6431523B2 (pt) |
| KR (1) | KR102367760B1 (pt) |
| CN (1) | CN105745226B (pt) |
| AU (1) | AU2014297217B2 (pt) |
| BR (1) | BR112016002001B1 (pt) |
| CA (1) | CA2919736C (pt) |
| DK (1) | DK3027656T3 (pt) |
| ES (1) | ES2736324T3 (pt) |
| HU (1) | HUE044469T2 (pt) |
| MX (1) | MX2016001193A (pt) |
| PL (1) | PL3027656T3 (pt) |
| RU (1) | RU2709741C2 (pt) |
| SG (2) | SG10201800592SA (pt) |
| TR (1) | TR201910330T4 (pt) |
| WO (1) | WO2015016386A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104284903B (zh) * | 2012-01-31 | 2020-10-09 | Sbi生物技术有限公司 | 抗磷脂酶d4抗体 |
| EP3484923A1 (en) * | 2016-07-15 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
| JP7140367B2 (ja) * | 2018-05-31 | 2022-09-21 | 国立大学法人 東京大学 | ヒト由来サンプルにおける可溶型ｔｌｒ７の分析 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69329503T2 (de) * | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| EP1107978A1 (en) * | 1998-08-24 | 2001-06-20 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
| AU2002239505A1 (en) * | 2000-12-07 | 2002-06-18 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of viral disease using 55092 |
| JP2013052781A (ja) | 2011-09-05 | 2013-03-21 | Tokai Rika Co Ltd | 車両用ミラー装置 |
| CN104284903B (zh) * | 2012-01-31 | 2020-10-09 | Sbi生物技术有限公司 | 抗磷脂酶d4抗体 |
-
2014
- 2014-07-30 SG SG10201800592SA patent/SG10201800592SA/en unknown
- 2014-07-30 US US14/908,004 patent/US20160168266A1/en not_active Abandoned
- 2014-07-30 HU HUE14761423 patent/HUE044469T2/hu unknown
- 2014-07-30 AU AU2014297217A patent/AU2014297217B2/en active Active
- 2014-07-30 TR TR2019/10330T patent/TR201910330T4/tr unknown
- 2014-07-30 ES ES14761423T patent/ES2736324T3/es active Active
- 2014-07-30 RU RU2016106708A patent/RU2709741C2/ru active
- 2014-07-30 BR BR112016002001-4A patent/BR112016002001B1/pt active IP Right Grant
- 2014-07-30 EP EP14761423.4A patent/EP3027656B1/en active Active
- 2014-07-30 MX MX2016001193A patent/MX2016001193A/es unknown
- 2014-07-30 JP JP2016503264A patent/JP6431523B2/ja active Active
- 2014-07-30 KR KR1020167002746A patent/KR102367760B1/ko active IP Right Grant
- 2014-07-30 SG SG11201600666SA patent/SG11201600666SA/en unknown
- 2014-07-30 CN CN201480047721.6A patent/CN105745226B/zh active Active
- 2014-07-30 DK DK14761423.4T patent/DK3027656T3/da active
- 2014-07-30 PL PL14761423T patent/PL3027656T3/pl unknown
- 2014-07-30 CA CA2919736A patent/CA2919736C/en active Active
- 2014-07-30 WO PCT/JP2014/070661 patent/WO2015016386A1/en active Application Filing
-
2018
- 2018-11-01 JP JP2018206702A patent/JP2019014759A/ja not_active Ceased
-
2019
- 2019-09-25 JP JP2019173621A patent/JP6843449B2/ja active Active
-
2020
- 2020-12-18 US US17/127,202 patent/US20210130493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2919736C (en) | 2022-03-22 |
| AU2014297217A1 (en) | 2016-02-18 |
| JP2019014759A (ja) | 2019-01-31 |
| ES2736324T3 (es) | 2019-12-27 |
| SG11201600666SA (en) | 2016-02-26 |
| RU2016106708A (ru) | 2017-09-01 |
| MX2016001193A (es) | 2016-05-26 |
| HUE044469T2 (hu) | 2019-10-28 |
| RU2709741C2 (ru) | 2019-12-19 |
| JP6843449B2 (ja) | 2021-03-17 |
| JP2019214621A (ja) | 2019-12-19 |
| CN105745226B (zh) | 2020-03-06 |
| RU2016106708A3 (pt) | 2018-03-30 |
| CN105745226A (zh) | 2016-07-06 |
| TR201910330T4 (tr) | 2019-07-22 |
| DK3027656T3 (da) | 2019-08-05 |
| PL3027656T3 (pl) | 2019-10-31 |
| JP6431523B2 (ja) | 2018-11-28 |
| KR20160034934A (ko) | 2016-03-30 |
| JP2016534022A (ja) | 2016-11-04 |
| SG10201800592SA (en) | 2018-03-28 |
| US20210130493A1 (en) | 2021-05-06 |
| CA2919736A1 (en) | 2015-02-05 |
| WO2015016386A1 (en) | 2015-02-05 |
| EP3027656A1 (en) | 2016-06-08 |
| US20160168266A1 (en) | 2016-06-16 |
| EP3027656B1 (en) | 2019-06-26 |
| BR112016002001B1 (pt) | 2023-04-25 |
| KR102367760B1 (ko) | 2022-02-24 |
| AU2014297217B2 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015027385A2 (pt) | Anticorpos modificados de ligação ao fcrn humano e métodos de uso | |
| BR112019023754A2 (pt) | anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. | |
| BR112016011401A2 (pt) | moduladores de aplnr e utilizações dos mesmos | |
| BR112018009064A8 (pt) | anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo | |
| BR112015023262B8 (pt) | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
| BR112018074155A2 (pt) | anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo | |
| BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
| BR112017023849A2 (pt) | anticorpos anti-ox40 e métodos de uso dos mesmos | |
| BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
| BR112017006178A2 (pt) | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos | |
| CR20130621A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
| BR112014018561A8 (pt) | Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
| BR112014031689A2 (pt) | anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles | |
| ECSP12012272A (es) | Proteínas que se unen al tnf-? | |
| BR112014021081A2 (pt) | anticorpos para a metaloproteinase da matriz 9 | |
| BR112016007112A2 (pt) | Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação | |
| BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
| BR112016001782A2 (pt) | Proteína de fusão terapêutica | |
| BR112019008417A2 (pt) | compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y | |
| BR112015004875A2 (pt) | formulações de anticorpo e seus usos | |
| BR112019005139A2 (pt) | anticorpos anti-il-33 e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/07/2014, OBSERVADAS AS CONDICOES LEGAIS |